Generalized Anxiety Disorder Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, MOA, ROA by DelveInsight | Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, MindMed, VistaGen Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Generalized Anxiety Disorder pipeline constitutes 10+ key companies continuously working towards developing 12+ Generalized Anxiety Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Generalized Anxiety Disorder Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Generalized Anxiety Disorder Market.

The Generalized Anxiety Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Generalized Anxiety Disorder Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Generalized Anxiety Disorder treatment therapies with a considerable amount of success over the years.

*
Generalized Anxiety Disorder companies working in the treatment market are Pear Therapeutics, Enveric Biosciences, OWP Pharmaceutic als, AbbVie, Cybin, Mind Medicine, Inc., Engrail Therapeutics INC, Otsuka Pharmaceutical, Luye PharmaGroup Ltd., and others, are developing therapies for the Generalized Anxiety Disorder treatment

*
Emerging Generalized Anxiety Disorder therapies in the different phases of clinical trials are- Pear-011, EVM201 Series, Duloxetine Hydrochloride , ABBV 932, CYB004, MM-120, ENX-102, Ulotaront, LY03005, and others are expected to have a significant impact on the Generalized Anxiety Disorder market in the coming years.

*
In March 2024, Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company specializing in advancing both traditional and innovative behavioral health treatments with a commitment to safe, evidence-based therapies, extends congratulations to Mind Medicine ("MindMed" NASDAQ: MNMD, Cboe Canada: MMED) on the positive outcomes of its Phase 2b clinical trial evaluating MM120 (lysergide d-tartrate) for generalized anxiety disorder ("GAD"). Results indicated that four weeks following a single 100-microgram dose of MM120, 48 percent of participants achieved remission with no clinically significant anxiety, and 65 percent experienced clinically meaningful improvement. Given the promising initial clinical findings and recognizing the substantial unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has granted MM120 for GAD a breakthrough therapy designation.

*
In December 2023, Mind Medicine (MindMed) has announced encouraging top-line results from its Phase IIb clinical study of MM-120 (lysergide d-tartrate) aimed at treating generalized anxiety disorder (GAD). The trial, which was double-blind, conducted across multiple centers, and involved dose optimization, enrolled 198 participants. These subjects were randomly assigned to receive either a single dose of 25g, 50g, 100g, 200g of MM-120, or a placebo.

*
In July 2023, Luye Pharma has started a Phase III clinical trial, conducted across multiple centers, employing a randomized, double-blind, and placebo-controlled approach. The trial aims to assess the effectiveness and safety of toludesvenlafaxine hydrochloride sustained-release tablets in individuals diagnosed with generalized anxiety disorder.

Generalized Anxiety Disorder Overview

Generalized Anxiety Disorder (GAD) is a mental health condition characterized by excessive, uncontrollable worry and anxiety about various aspects of life.

Get a Free Sample PDF Report to know more about Generalized Anxiety Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/generalized-anxiety-disorder-pipeline-insight [https://www.delveinsight.com/report-store/generalized-anxiety-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Generalized Anxiety Disorder Drugs Under Different Phases of Clinical Development Include:

*
Pear-011: Pear Therapeutics

*
EVM201 Series: Enveric Biosciences

*
Duloxetine Hydrochloride : OWP Pharmaceutic als

*
ABBV 932: AbbVie

*
CYB004: Cybin

*
MM-120: Mind Medicine, Inc.

*
ENX-102: Engrail Therapeutics INC

*
Ulotaront: Otsuka Pharmaceutical

*
LY03005: Luye PharmaGroup Ltd.

Generalized Anxiety Disorder Route of Administration

Generalized Anxiety Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intravenous

*
Oral

*
Intramuscular

Generalized Anxiety Disorder Molecule Type

Generalized Anxiety Disorder Products have been categorized under various Molecule types, such as

*
Small molecules

*
Peptides

Generalized Anxiety Disorder Pipeline Therapeutics Assessment

*
Generalized Anxiety Disorder Assessment by Product Type

*
Generalized Anxiety Disorder By Stage and Product Type

*
Generalized Anxiety Disorder Assessment by Route of Administration

*
Generalized Anxiety Disorder By Stage and Route of Administration

*
Generalized Anxiety Disorder Assessment by Molecule Type

*
Generalized Anxiety Disorder by Stage and Molecule Type

DelveInsight's Generalized Anxiety Disorder Report covers around 12+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Generalized Anxiety Disorder product details are provided in the report. Download the Generalized Anxiety Disorder pipeline report to learn more about the emerging Generalized Anxiety Disorder therapies [https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Generalized Anxiety Disorder Therapeutics Market include:

Key companies developing therapies for Generalized Anxiety Disorder are - Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, MindMed, VistaGen Pharma, Actavis, Takeda Pharma, Bionomics, GSK, Pfizer, Bristol-Myers Squibb, Actavis Pharma, and others.

Generalized Anxiety Disorder Pipeline Analysis:

The Generalized Anxiety Disorder pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Generalized Anxiety Disorder with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Generalized Anxiety Disorder Treatment.

*
Generalized Anxiety Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Generalized Anxiety Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Generalized Anxiety Disorder market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Generalized Anxiety Disorder drugs and therapies [https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Generalized Anxiety Disorder Pipeline Market Drivers

*
Soaring Applications of Cognitive Behavioral Therapy for Generalized Anxiety Disorder are Expected to Boost the Growth, increasing Predominance of Generalized Anxiety Disorder are some of the important factors that are fueling the Generalized Anxiety Disorder Market.

Generalized Anxiety Disorder Pipeline Market Barriers

*
However, poor diagnosis rate of generalized anxiety disorder owing to the lack of a suitable diagnosis test, limited access to mental health services and other factors are creating obstacles in the Generalized Anxiety Disorder Market growth.

Scope of Generalized Anxiety Disorder Pipeline Drug Insight

*
Coverage: Global

*
Key Generalized Anxiety Disorder Companies: Pear Therapeutics, Enveric Biosciences, OWP Pharmaceutic als, AbbVie, Cybin, Mind Medicine, Inc., Engrail Therapeutics INC, Otsuka Pharmaceutical, Luye PharmaGroup Ltd., and others

*
Key Generalized Anxiety Disorder Therapies: Pear-011, EVM201 Series, Duloxetine Hydrochloride , ABBV 932, CYB004, MM-120, ENX-102, Ulotaront, LY03005, and others

*
Generalized Anxiety Disorder Therapeutic Assessment: Generalized Anxiety Disorder current marketed and Generalized Anxiety Disorder emerging therapies

*
Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder market drivers and Generalized Anxiety Disorder market barriers

Request for Sample PDF Report for Generalized Anxiety Disorder Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Generalized Anxiety Disorder Report Introduction

2. Generalized Anxiety Disorder Executive Summary

3. Generalized Anxiety Disorder Overview

4. Generalized Anxiety Disorder- Analytical Perspective In-depth Commercial Assessment

5. Generalized Anxiety Disorder Pipeline Therapeutics

6. Generalized Anxiety Disorder Late Stage Products (Phase II/III)

7. Generalized Anxiety Disorder Mid Stage Products (Phase II)

8. Generalized Anxiety Disorder Early Stage Products (Phase I)

9. Generalized Anxiety Disorder Preclinical Stage Products

10. Generalized Anxiety Disorder Therapeutics Assessment

11. Generalized Anxiety Disorder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Generalized Anxiety Disorder Key Companies

14. Generalized Anxiety Disorder Key Products

15. Generalized Anxiety Disorder Unmet Needs

16 . Generalized Anxiety Disorder Market Drivers and Barriers

17. Generalized Anxiety Disorder Future Perspectives and Conclusion

18. Generalized Anxiety Disorder Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=generalized-anxiety-disorder-pipeline-trends-2024-clinical-trials-therapeutic-innovations-moa-roa-by-delveinsight-pfizer-inc-glaxosmithkline-eli-lilly-and-company-mindmed-vistagen-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.